Complete Story
02/17/2021
Additional Indication: Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki)
On January 15, 2021, the U.S. Food & Drug Administration approved an additional indication for ENHERTU® (fam-trastuzumab deruxtecan-nxki), for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. ENHERTU has Boxed WARNINGS for Interstitial Lung Disease (ILD)/Pneumonitis and Embryo-Fetal Toxicity. Please see Important Safety Information below.
This additional ENHERTU indication does not affect its existing package information1,2:
Description |
Vial size |
Billing Units |
NDC |
J-code |
Injection, fam-trastuzumab deruxtecan-nxki, 1mg |
One 100 mg single-dose vial |
100 units |
65597-406-01 |
J9358 |
As a reminder, the ENHERTU4U website contains a suite of Access and Reimbursement resources and program information. Please visit https://www.enhertu4u.com/ for more information.
If you have questions or would like support, you can also contact me directly or reach out to an ENHERTU4U care counselor at 1-833-ENHERTU (1-833-364-3788), Monday through Friday, 8 AM—8 PM ET.
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!